B cell tolerance in mice transgenic for anti-CD8 immunoglobulin mu chain by unknown
B  Cell Tolerance in Mice Transgenic for Anti-CD8 
Immunoglobulin/~  Chain 
By Frank Brombacher, Georges K6hler, and Hermann Eibel 
From the Max-Planck-Institut fiir Immunbiologie, 7800 Freibur,~ Germany 
Snrrll'nary 
To analyze in vivo the induction of B cell tolerance against a T cell surface antigen, we generated 
transgenic mice expressing an anti-CD8.2/~ heavy chain gene. We show that self-specific B cells 
are efficiently tolerized if they express the membrane-bound form of the transgenic/~ chain on 
their surface but that they can escape tolerization if they express only the secreted form. In the 
latter, we find an enhanced expression of anti-CD8.2 antibodies after polyclonal B cell activation. 
As a result, transgenic anti-CD8.2 antibodies bind to the CD8 § T cells but they did not induce 
their elimination. Furthermore, we observed the preferential expression of a limited subset of 
endogenous light chains with the transgenic/~ chain. This suggests a positive or negative selection 
for particular heavy and light chain combinations in B lymphocytes. 
T 
olerance to self is one of the key properties of the im- 
mune system. To. explain the generation and the expan- 
sion of self-reactive B lymphocytes, several regulatory mech- 
anisms have been either postulated  (1-3)  or documented. 
Self-reactive clones were shown to be clonally deleted (4-6), 
to be functionally inactivated by clonal anergy (7-12), to be 
suppressed (13, 14), and to be controlled by virtue of antiidi- 
otypic network interactions (3). 
The low frequency of self-reactive clones in healthy animals 
with a wide range of autoantibody affinities  hampered the 
in vivo analysis of the origin and fate of autoreactive B lym- 
phocytes. These restrictions were overcome by creating trans- 
genic mice whose B cells express autoreactive antibodies of 
defined affinity (5,  6,  8-12).  In the absence of the autoan- 
tigen, the transgenic receptors are expressed by nearly all B 
lymphocytes of these mice. Their fate in the autoreactive sit- 
uation was analyzed by introducing the autoantigen in matings 
to appropriate mouse strains. Several recent investigations have 
been carried out analyzing the reaction of self-reactive B cells 
to either soluble (6,  8-12) or membrane-bound (5,  6) au- 
toantigens. In these studies, the B cell repertoire of the au- 
toreactive transgenic mice was either nearly monospecific due 
to the presence of transgenic heavy and light chains (5,  6, 
8-12) or showed a high degree of permissiveness in the light 
chain usage in mice transgenic for the autoreactive heavy 
chain (12). 
We chose as autoantigenic determinant an epitope present 
on the CD8 oe chain expressed on the surface of T cells. Two 
alleles, CD8.1  and CD8.2,  of the CD8 ol chain are found 
in mice. They differ by the exchange of a single amino acid: 
a methionine residue located in the V-like domain of the CD8.2 
ol chain is replaced by valine in the CD8.1 a  chain (15). Only 
the CD8.2 allelic form is recognized by a mAb produced by 
the hybridoma line 19/178 (16) from which we cloned the 
antibody genes. To allow a certain degree of variability within 
the B cell repertoire, we introduced only the functionally rear- 
ranged anti-CD8/z heavy chain into the germline of mice 
(17). The selection of the anti-CD8.2 self-specificity was then 
allowed by the combination of the transgenic anti-CD8.2 # 
chain with endogenous light chains. To study B lymphocyte 
tolerance, we introduced the anti-CD8.2 #  transgene into 
mice expressing either the CD8.1  or the CD8.2 allele. We 
then examined the expression of the transgene by B lympho- 
cytes, the tolerance status of these mice, the contribution of 
a functional T cell compartment, the role of membrane im- 
munoglobulin expression, and the influence of polyclonal B 
cell activation on the tolerization of autoreactive B cells. 
Materials and Methods 
Mice.  C57BL/6 and CD8.1 + congenic ~816 strains were kept 
and bred in the animal breeding facility under specific pathogen- 
free conditions. The production of the transgenic lines M4, M12, 
M8Y, M42, and M85 is described (17). The lines were backcrossed 
to C57BL/6  and B16. 
Antibodies.  mAbs to mouse IgM, M41 specific for C~3, (18), 
RS3.1 for IgM  ' (19), MB86 for IgM  b, 19/178 for the CD8.2  c~ 
chain (16), and RA3.3A1 for B220 (20) were conjugated with FITC 
(Research Organics, Cleveland, OH) or biotin  (longarm biotin; 
Zymed, San Francisco, CA),  according to Hardy (21). FITC-, 
biotin-, or PE-labeled anti-mouse CD8 (53-6.7) and anti-mouse 
CD4  (GK1.5) were purchased from Becton Dickinson  &  Co. 
(Mountain View, CA); labeled anti-mouse IgG2A sera were from 
Southern Biotechnology Associates (Heidelberg, FRG). The con- 
centration of IgM' in mouse serum was determined by ELISA. 96- 
well microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) were 
coated with RS3.1 at 10/~g/ml in PBS and blocked with 1% BSA. 
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pernatant and an appropriate standard of mouse IgM" and devel- 
oped with  a phosphatase-coupled goat-anti  mouse IgM  serum 
(Southern Biotechnology Associates) andp-nitrophenyl phosphate 
(Sigma  Chemical Co.,  Munich,  FRG) as substrate.  Plates  were 
washed three times in between each step with PBS, 0.05% Tween 
20,  0.1%  azide in order to reduce background. 
Complement-dependent Cell Lysis.  Thymocytes from CD8.2 § 
C57BL/6 or CD8.1 §  mice were incubated (106/ml, 80-90% 
CD8 +) with serial dilutions of culture supernatants of transfec- 
tants or of mouse serum in a total volume of 50 #1 together with 
1/8 volume of Low Tox-M rabbit complement (Cedarlane Labs Ltd., 
Hornby, ON) at 4~  for 30 min. Dead cells were identified by 
inclusion staining using trypan blue (Sigma Chemical Co.). If>50% 
of the CD8.2 + target cells were lysed, the sera were scored as posi- 
tive for containing anti-CD8.2 antibodies.  Unspecific background 
lysis was observed at ',~10%. 
Flow Cytometry.  Flow cytometry was performed as described 
(17).  Briefly,  103  to  106 viable  cells  were incubated  in  a  total 
volume of 20 ~1 with PE-, biotin-, or FITC-coupled antibodies 
at 4~  for 20 rain in PBS buffer containing 3% FCS, 0,1% sodium 
azide. They were counterstained if required with PE-Streptavidin 
complex (Southern Biotechnology Associates).  Dead cells were 
identified with propidium iodide and excluded from the analysis. 
All analyses were performed using a FACScan  |  flow cytometer 
(Becton Dickinson & Co.), with FACScan  |  and LYSYS software 
programs. 
Isolation of Hybridomas and Analysis of  Antibody Specificities.  Hy- 
bridomas were obtained after fusion of spleen calls with the HAT- 
sensitive Ig-negative myeloma line X63Ag8.0 after 2 wk of cul- 
ture in HAT-supplemented Iscove's medium (Gibco Laboratories, 
Karlsruhe,  FRG).  Cells  were either in vitro stimulated with  10 
#g/ml LPS EH100 (Sigma Chemical Co.) before the fusion or in 
vivo by injecting 5 #g of purified LPS (EH100, kindly provided 
by Chris Galanos, MPI, Freiburg) directly into the spleen of mice. 
Spleen cells were then isolated  4 d later and fused to X63Ag8.0 
using PEG 1500 (Boehringer Mannheim Corp., Mannheim, FR.G). 
IgMa-positive  clones  were identified by ELISA.  CD8.2-specific 
clones were identified by screening supernatants  first in a cell ELISA 
followed by flow cytometric analysis using supernatants of positive 
clones. Alternatively, supernatants were directly screened by flow 
cytometry. For the cell ELISA, supernatants were incubated in 96- 
well U-bottomed microtiter plates in a total volume of 100/xl for 
1 h  at 40C with  103 CD8.2 ~ and CD8.1 + thymocytes, respec- 
tively. Cells were washed three times in PBS, 3% FCS, and bound 
IgM  a molecules were detected by incubating them with peroxi- 
dase-coupled  goat anti-mouse IgM antiserum (Southern Biotech- 
nology). Excess antibodies were removed by washing the cells three 
times in PBS, 3% FCS. Anti-CD8.2 binding was visualized using 
2 mM 2,2'-azino-di-[3-ethylbenzthiazolin-sulfonate]  (~;  Boehr- 
inger Mannheim Corp.) in 100 mM citric acid buffer containing 
0.03% H202, pH 4.6. The green color reaction was stopped using 
azide and the A410 was measured using an ELISA reader. Positive 
clones were identified by comparing the reaction of CD8.2 + vs. 
CD8.1 + thymocytes. Their CD8.2 specificity was further corrobo- 
rated  by  FACS  |  analysis.  Supernatants  were  incubated  with 
CD8.2 + and CD8.1 § thymocytes, respectively (see Fig. 3). Specific 
binding was visualized using FITC- or PE-labeled goat anti-mouse 
serum (Southern Biotechnology). The binding properties of some 
of the CD8.2-specific supernatants were further tested for their 
capacity to inhibit the CD8.2-specific binding of 19/178 using flow 
cytometry. The actual number of IgM~-positive hybrids was cal- 
culated from dilution plates  using the Poisson distribution. 
Isoelectric Focusing (IEF) and Western Blotting.  For IEF-PAGE 7.0% 
polyacrylamide gels, including 7 M urea and ampholines ranging 
from pH 5-7, pH 7-9, and pH 3-10 (Pharmacia  Fine Chemicals, 
Freiburg,  FKG), were used. Fresh supernatants  (2-4 #1) from over- 
night cultures of hybridomas were reduced in 9 M urea and 10% 
B-mercaptoethanol at 37~  for 30 min and then applied onto the 
gel. Vertical gels were run at 700 V for 16 h. The proteins were 
transferred electophoretically to nitrocellulose filters (Schleicher and 
Schtill, Dassel,  FRG). g light chains were identified using horse- 
radish  peroxidase (HRPO)l-labeled goat anti-mouse g chain an- 
tibodies (Southern Biotechnology) at ~250 ng/ml. Bound HRPO- 
antibody complexes were visualized  using an enhanced chemilu- 
minescence Western blotting detection system (Amersham Corp., 
Braunschweig, FRG). 
Cell.mediated  Lysis  Assay.  K46  (22)  and  anti-CD8.2  /~/g- 
transfected K46pp target cells were labeled with 200 #Ci 51Cr- 
NazCrO~  (DuPont  Co.,  Wilmington,  DE)  in  400  #1  culture 
medium followed by four wash steps to remove unincorporated ra- 
dioactivity. As cytotoxic effector cells, we used the H2  b§  CD8.2 + 
lines CL96 specific for a P815 antigen presented with H2K  a (23), 
Tl12-3.2 (TNP specific, H2K  b restricted),  and LD26.10.3-3  (H2D  d 
specific), kindly provided by Bodo Ortmann (MPI, Freiburg). 2 
x  103 target cells/well were incubated with or without 0.5% 
PHA in 96-weU plates (NUNC). Effector cells were added in tripli- 
cates at different dilutions to a total volume of 200 #1. Samples 
were incubated for 4 h at 37~  in 7% CO2. Cells were pelleted 
by centrifugation (1,200 rpm, 10 min), and released. SlCr was ana- 
lyzed in 100/~1 of their supernatants using a gamma counter. Specific 
lysis was calculated as: percent specific lysis =  100 x  (experimental 
release  -  spontaneous release)/(detergent release  -  spontaneous 
release). 
DNA Constructs.  The anti-CD8.2 # chain containing plasmid 
pC#19E was described (17). It was used for transfection experi- 
ments and it also served as a source for the isolation of the frag- 
ments used to generate the transgenic mice. The anti-CDS.2 g light 
chain  was  cloned according to  standard  protocols (24)  from a 
genomic library made with partially Sau3A-digested and size-selected 
(10-20 kb) 19/178 DNA ligated to BamHI/EcoRI double-digested 
EMBL3 DNA (Amersham Corp.). Ligations were packaged in vitro 
(GigaPack gold; Stratagene,  Heidelberg, FKG) and plated on the 
Escherichia coli strain  Q359  (supE,  hsdR,  ~80  r,  P2).  K-positive 
clones were identified by plaque screening using a 0.9-kb HindlII- 
XbaI intron fragment of the mouse g gene as a probe. They were 
further subcloned into the vector p72hyg, a derivative of the plasmid 
pSP72 (Promega Corp., Heidelberg, FKG) into which we inserted 
a hygromycin resistance gene controlled by HSV-tk promoter and 
polyadenylation sequences in order to allow expression  of hygro- 
mycin resistance in murine cell lines. The clone, named pg19, con- 
tains the anti-CD8.2 g gene including the 5' and the 3' g enhancer. 
It is based on the vector p72hyg and was used in all further ex- 
periments. 
Transfections.  The myeloma line X63Ag8.0 was transfected using 
lipofection (25) and Lipofectin (Gibco Laboratories,  Grand Island, 
NY).  For cotransfection of pC#19E (G418 R) and pg19 (Hygr~), 
equal amounts (20 #g) of supercoiled  plasmid DNA were used. 
Positive transfectants (X63/c~CDS.2) were double selected in Iscove's 
modified DMEM containing 10% FCS (Gibco Laboratories)  sup- 
plemented with 1 mg/ml G418 (Gibco Laboratories) and 400 #g/ml 
hygromycin (Sigma Chemical Co.). The B cell lymphoma line K46 
was cotransfected with both plasmids by electroporation according 
t Abbreviation used in this paper: HRPO, horseradish peroxidase. 
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stead of buffer and a capacitor set at 450 #F charged with 250 V. 
Positive clones (K46pp) were selected  with 0.8 mg/ml G418 (Gibco 
Laboratories) and 300 #g/ml hygromycin. Their specificity for 
CD8.2 was tested by analyzing supernatants using flow cytometry. 
Results 
Expression of the Transgenes.  We cloned the heavy and light 
chain antibody genes from the anti-CD8.2 hybridoma line 
19/178  (16).  The V  region of the anti-CD8.2 heavy chain 
gene  was  linked  to  the  c~  constant  region  and  used  to 
generate two different sets of transgenic mice (17). The first 
set contains an Ig #  transgene (#19  'm) encoding the mem- 
brane (IL/,  m) and the secreted (#') form of the #  heavy chain 
(Fig. 1 A, lines M4, M12, and M8Y). The transgenic # chain 
is expressed in B cells and forms in combination with endog- 
enous light chain IgM  '  molecules. Using allotype-specific 
antibodies, they can be distinguished from the endogenous 
IgM  b molecules that  are found in the C57BL/6  and/516 
strains.  The tolerization of B lymphocytes requires the sur- 
face expression of autoreactive Igs in order to ensure signal 
transduction via the Ig antigen receptor complex (27,  28). 
Since the B cells of the #19  ~m mice express the anti-CD8.2 
# heavy chain in combination with endogenous light chains 
on their surface (Fig. 2; Table 1), they were used used to ana- 
lyze the role of surface Ig globulin antigen receptor com- 
plex. The second set (#19 ~) has integrated into its germline 
a truncated version of the #  gene (17) lacking both trans- 
membrane exons C~,5 and C~6  (Fig.  1 B,  lines M42  and 
M85). As a result, only the secreted form (#') of the trans- 
genic/~ chain can be expressed (Fig.  2; Table 1). B cells that 
can only produce the secreted form of anti-CD8  autoanti- 
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Figure 1.  Map of the transgenes. The #19  'm transgenic lines M4, M12, 
and M8Y were generated by microinjecting  nuclei of fertilized eggs with 
the Aat2-SphI fragment shown in A (17). The fragment carries the com- 
plete anti-CD8.2 # chain. Line M8Y has the transgene integrated on its 
Y chromosome. The #19  ~  lines M42 and M85 carry the Aat2-KpnI frag- 
ment shown in B. Here, the transmembrane exons of the/~ chain are lacking. 
It is therefore expressed only in the form of secreted IgM molecules. (Thin 
line) Phsmid (pUC19)-derived sequences; (thick line) murine genomic DNA. 
(I) Coding sequence of the L, V, C~,1, C~2, C~3, C~4, C~5, Cu6, exons, 
(O) polyadenylation sites, (')  heavy chain intron enhancer. 
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body molecules should not form a target for the tolerizing 
mechanism. The #19' mice were used to test this prediction. 
Tolerance in Mice Expressing Surface IgM; No Tolerance in 
Mice Expressing only Secreted IgM Antibodies.  The combina- 
tion of an appropriate light chain with the transgenic # chain 
should eventually result in anti-CDS.2 IgM" antibodies. In 
transgenic mice with a CD8.2 background, we expected such 
autoreactive cells to be deleted or to be inactivated. To follow 
this process, we analyzed tolerance induction in #19 'm mice 
directly in vivo for all B cells as well as in vitro at a single 
cell level. 
For the in vivo analysis,  we tested the presence of anti- 
CD8.2 IgM  '  antibodies in sera of/~19  sm mice in a comple- 
ment-dependent cell lysis assay and by flow cytometry (Table 
1). In the presence of the CD8.2 antigen, i.e., in a C57BL/6 
background, we were unable to detect anti-CD8.2 antibodies 
as reflected by the lack of cytolytic activity against CD8.2 + 
target cells. In the absence of the CD8.2 antigen, i.e., in a 
CD8.1 + syngeneic/516 background, almost all tested sera 
showed cytolytic activities  against CD8.2 § thymocytes. The 
specificity of the IgM  ~ antibodies  for CD8.2  was  further 
verified by a flow cytometric test (Table  1). In/~19  sm with 
a CD8.2 § C57BL/6 background, we were unable to detect 
anti-CD8.2 serum antibodies. This could be due to their com- 
plete adsorption to CD8.2 molecules present on the surface 
of T  cells. This, however, is unlikely, since we found IgM  ~ 
anti-CD8.2 antibodies in the sera of 6 of 16/~19 s mice with 
a CD8.2 + C57BL/6 background, (Table  1). The failure to 
detect anti-CD8.2 antibodies in the presence of the CD8.2 
antigen  suggests  that  B  lymphocytes of ~19  ~m transgenic 
mice are tolerized. 
Our analysis of the serum antibody reactivities against CD8 
surface molecules does not allow the differentiation between 
clonal deletion or inactivation of autoreactive B cells. In ad- 
dition, anti-CD8.2 autoantibodies present in low amounts 
would not have been detected. We therefore investigated at 
a single cell level the proportion of CD8.2-specific B cells 
within the splenic B lymphocyte population.  Hybridomas 
were generated from in vitro LPS-activated spleen cells de- 
rived from the transgenic lines and tested for the expression 
of the transgenic #~ chain and for their anti-CD8.2  spec- 
ificity (Table 2; Fig. 3, A and B). The expression of the trans- 
genic #  chain before light chain rearrangement could have 
an influence on the selection of endogenous light chains by 
the B cells. We therefore also analyzed the frequency of CD8.2- 
specific hybridomas derived from unselected B cells by fusing 
spleen cells from C57BL/6 or/516 mice to a transfectant of 
the myeloma line X63Ag8.0 expressing the transgenic anti- 
CD8.2 # chain (X63/#19, fusion A). CD8.2-specific hybrid- 
omas were found in 1 of 200 hybridomas (1/100 to 1/480, 
fusion A). This result was then compared to the frequency 
of transgenic anti-CD8.2 hybridomas derived from CD8.1 + 
~16  /~19  'm spleen cells  (Table  2,  fusion B).  Here, we also 
found in 1 of 200 (1/60 to  1/313)  clones reconstitution of 
the original anti-CD8.2 specificity (fusion B). This compar- 
ison shows that the frequency for anti-CD8.2 antibodies was 
almost identical in both types of fusions using either trans- 
genic B cells from CD8.1 + /z19  sm mice (fusion B) or B cells i'M 
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Figure 2.  Expression of the transgenes in spleen 
cells. For flow cytometry, splenocytes were double 
stained  with  either  RS3.1  (transgenic  IgM= in 
fluorescence 2;  PE)  and M86  (endogenous  IgM  b 
molecules in fluorescence 1; FITC) or with RS3.1 
and RA3.3A1  detecting  the B cell marker B220 
(fluorescence 1; FITC). Cells of a/~19'm transgenic 
line (M4) and of a/~19  ~ transgenic line (M85) were 
compared to control mice (CL; all mice were 6-8 
wk old). Flow cytometry was carried out as described 
in Materials  and Methods using a large foreward/side- 
ward scatter gate during acquisition and a small gate 
characteristic for B lymphocytes during analysis.  The 
relative percentage of cells is given in each quadrant 
or  region.  ('/bp) M4  spleen cells (IgM'-IgM  b+ 
C57BL/6  background)  stained for IgM=/IgM b or 
IgM=/B220 compared to an heterozygous IgM  ~+ / 
IgM  b+ control mouse (CL) obtained from M4  x 
(C57BL/6  x  BALB/c)F1. The #19  'm transgene in 
M4 is expressed by most of the B220 + cells (26% 
IgM~B220  +) resulting in a strong allelic exclusion 
for endogenous IgM  b (36% IgM  -+, 0.6% IgMb+). 
This is also reflected by a strong reduction in the 
IgM~a~  +  population  (IgM~hiB220  +/IgMlo/ 
B220  hi  =  26/9  in  M4;  11/21  in  CL).  The 
IgM=-B220 + (37%) population represents B cells 
expressing the IgM  b allele (data not shown). (Middle 
and bottom) Comparison between M85 (/~19') and 
a control animal (CL; IgM  ~- IgM  b  + in a C57BL/6 
background)￿9 The product  of the/x19, transgene 
lacks the C~5 and C,6 transmembrane exons (Fig. 
1 B) preventing its membrane insertion. Due to the 
lack of allelic exclusion (49% IgM  s+ cells in M85), 
it is coexpressed with endogenous #  chains in the 
form of mixed molecules. They can be found on the 
surface of B cells using the IgM  b membrane do- 
mains as anchor (2.4% IgM'+B220  + cells in M85). 
from normal mice fused to the X63/#19 transfectant (fusion 
A). Therefore, the expression of the anti-CDS.2 #  chain in 
transgenic mice does not result in the increased formation 
of anti-CDS.2-specific B cells. Anti-CD8.1-specific hybrid- 
omas were not found when supernatants were tested for their 
ability to bind  to CD8.1 §  thymocytes. 
As was already expected from the analyses  of the trans- 
genic sera, mice expressing the antigenic CD8.2 allele proved 
to be tolerant.  Among >6,700 tested hybridomas from the 
#19  'm  lines  M4,  M12,  and  MSY,  none  was  found  to  be 
CD8.2 specific (fusion C). The >30-fold reduction of CDS.2- 
specific B cells suggests that in the presence of the antigenic 
CD8.2  ot  chain  even  rare  splenic  anti-CD8.2  B  cells  are 
efhciently  counterselected.  Some of our  /z19  sm  transgenic 
lines like M4 and M12 suffer from a severe blockade in thymo- 
cyte development (17).  Their maturation  is arrested before 
the stage of CD4§  + double-positive cells  at the stage of 
IL-2RhiHSA hi thymocytes (our  unpublished  results).  As  a 
consequence, the more mature T cell populations in the thymus 
are highly reduced in size (10-60-fold). This leads to an ap- 
proximately fivefold reduction of their splenic T cells. This 
T  cell deficiency,  however, does not influence the toleriza- 
tion of B cells. A comparison between lines suffering from 
the thymocyte differentiation block (M4, M12) and a different 
/x19  sm line with a normal T cell complement (M8Y) revealed 
no difference in the manifestation of B cell tolerance (Table 
2, fusions C1-C6 and C9 for M4 and M12; fusions C7 and 
C8 for MSY). 
In  contrast  to  the  /~19  sm lines  (M4,  M12,  MSY),  some 
mice of the/x19 s lines M42 and M85 were capable of syn- 
thesizing anti-CD8.2 serum antibodies even in the presence 
of the antigen  (Table  1). Their majority, however, showed 
no detectable anti-CDS.2 activities in their sera. This differ- 
ence  between  individual  #19  TM  mice  may  be  due  to  the 
lacking allelic exclusion of endogenous heavy chain expres- 
sion in #' transgenic mice (17, 29). In both/~19 + lines,  the 
B cells coexpress transgenic  #19' chains together with en- 
dogenous/~ chains (17). As a consequence, in some animals 
the serum concentration  of anti-CD8.2  antibodies may be 
below our detection limit.  To test their tolerance status at 
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Figure 3.  Flow cytometric analysis 
of hybridoma supernatants for CD8.2 
specificity. (A)  CD8.2 +  thymocytes 
from C57BL/6 mice (lanes I-5) and 
from the CD8.1 + congenic strain •16 
(lanes 6-10) were stained with  the 
FITC-labeled  CD8.2-specific  IgG2A an- 
tibody 19/178 (lanes 1 and 7), with the 
FITC-labeled IgM,-specific antibody 
R83.1  (lane 2)  and with  the  CDS- 
specific antibody  53-6.7 (lane 6)  as 
controls. CDS.2-specific, IgM  "+  hy- 
bridoma supernatants of the fusions A 
(A49, lanes 3 and 8), D (D39, lanes 4 
and 9), and B (B107, lanes 5 and 10) 
were first incubated with thymocytes 
and then counterstained with FITC- 
labeled RS3.1. The supematants bind 
only to CD8.2 § but not to CD8.1* 
thymocytes.  (13) Thymocytes from 
CD8.2* C57BL/6 mice were first in- 
cubated with B107 (see legend to A) 
supematant and  then  counterstained 
with  the  IgM~-specific FITC-labeled 
antibody RS3.1 (a). In b, thymocytes 
were preincubated with an excess  of  un- 
labeled 19/178, then with B107 super- 
natant, and counterstained with RS3.1. 
The preincubation with 19/178 inhibits 
binding of the B107 supematant. FITC- 
labeled RS3.1 alone (c) does not bind 
to thymocytes. (d) Positive control for 
19/178 binding:  cells were first in- 
cubated with 19/178 and then counter- 
stained with FITC-labeled goat anti- 
mouse ")'2a antibodies. 
a single cell level, we therefore generated hybridomas from 
both #19' lines using spleen cells that were activated with 
LPS before the fusion. CD8.2-specific clones were obtained 
in both lines  at  a frequency of 1/858 IgM'-positive clones 
(Table  2,  fusion D). 
Our  hybridoma  analysis  suggested  that  the  /~19  ~ mice 
were not tolerant.  Therefore,  we were interested  to deter- 
mine whether it would be possible to increase the in vivo 
levels of anti-CD8.2  antibodies.  We activated their B cells 
polyclonaUy by injecting LPS either intravenously or directly 
into the spleen.  After 4 d,  their splenocytes were analyzed 
by flow cytometry for CD8 + T  cells with  IgM molecules 
bound to their  surface.  Three control littermates,  six #19' 
mice of the  M42  line,  seven #19  'm mice with  a  CD8.2 + 
C57BL/6 background (four mice of the M4 line and three 
of the MSY line),  and  two  #19  'm mice from the M4  line 
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Anti-CD8.2  serum 
specificity in: 
IgM  ~ serum  Percent  IgM  ~§  Complement 
Transgene line  Age  Cells/spleen  titer  cells/spleen  lysis*  FACS  ~* 
Wk  ￿  I0  7  /zg/ml 
#19 sm 
M4 (B/6)  4-16  2.0s  1-8  36  0/411  0/4911 
M4 (316)  8,  12  4.2 'l  2,  7  32  4/4  20/23 
M8Y (B/6)  10,  14  5.81  4, 6  28  ND  ND 
#19' 
M42 and M85 (B/6)  4-13  5.5**  3-14  2  1/9  6/16 
Control  4-17  8.2**  0  0  ND  ND 
" Anti-CD8.2 lytic activity in sera was  tested as described in Materials and Methods using CD8.1 +  and CD8.2 §  thymocytes as  target cells. 
* Anti-CDS.2 antibodies present in sera were analysed by flow cytometry using CD8.1 +  and CD8.2 +  thymocytes as target cells  as described in 
Materials and Methods. 
S Six mice were analyzed. 
rl Number of positive/number of tested mice. 
I Two mice were analyzed. 
** Seven mice were analyzed. 
** In total,  12  control littermates were analyzed. 
with a CD8.1 § /516 background were tested. All analyses 
gave very similar results, and the data of a representative analysis 
are shown in Fig.  4.  All CD8 + splenic T  cells of the/z19 s 
line M42 had IgM  '  molecules bound on their surface (Fig. 
4 A, M42/BL6).  The bound IgM was composed from hy- 
brid molecules formed by transgenic (IgM  ', Fig. 4 A) and 
endogenous (IgM  b, Fig. 4 B)/x chains. This result supports 
our observation that #19 s mice are not tolerant. In the/.t19  sm 
line M4, we did not observe the induction of transgenic high 
affinity anti-CD8.2  antibodies after injection of LPS.  This 
suggests that the tolerance state of the B cells in/z19  ~m mice 
cannot be broken by polyclonal B cell activation. 
The Direct Interaction of Anti-CDS.2 Antibodies on the Sur- 
face of  B Cells with CD8 on Cytotoxic T Cells Does Not Induce 
Cytolysis.  A potential mechanism of eliminating the anti- 
CDS.2-reactive B cells would be their cytolysis. Direct inter- 
actions between the surface anti-CD8.2 antigen receptor on 
B cells and CD8 molecules on cytotoxic T  cells could pos- 
sibly bring both cell types into close contact, induce cyto- 
toxic effector functions, and result in a killing reaction medi- 
ated by the CD8 + cytotoxic T cells. We tried to investigate 
this potential elimination mechanism by mimicking the reac- 
tion in vitro using a ceU-mediated lympholysis assay. To ob- 
tain a B lymphocyte  population that homogeneously expresses 
the anti-CD8.2 IgM  a antigen receptor on the membrane, we 
cotransfected the B lymphoma line line K46 (22) with vectors 
encoding the anti-CDS.2-specific/~ and K chain. An anti- 
CD8.2 IgMa-positive K46 transfectant (K46pp) was labeled 
with SlCr and coincubated with two different CD8.2 § CTL 
lines (CL96 and Tl12.3-2). Cytotoxicity was then analyzed 
with varying effector to target cell ratios and compared to 
lectin (PHA)-mediated killing that can induce the approxi- 
mation of CTL and target cells also in the absence of an- 
tigen. None of the tested cytotoxic T  cell lines was able to 
lyse the transfectant in the absence of PHA (Fig.  5, A  and 
B). As a control for the antigen-specific killing, we analyzed 
the cytotoxic activity of the H2Da-spedfic line LD26.10.3-3 
against the H2D a MHC class I molecules expressed on the 
surface of the K46pp transfectant. Here, both antigen-specific 
and lectin-mediated killing was observed (Fig. 5 C). Interest- 
ingly, we found a slight reduction in SlCr  release  for the 
K46pp transfectant by changing the E/T cell ratios and by 
varying the incubation time in all lectin-mediated killing assays 
as compared to the untransfected K46 controls. The abroga- 
tion of effector function has been reported before by blocking 
CD8 surface molecules using soluble 19/178 anti-CD8.2 an- 
tibodies (30).  The resistance of K46 transfectants to killing 
suggests that also membrane-bound anti-CD8 antibodies may 
cause inhibition of the cytotoxic activity. In analogy, anti- 
CD8 B cells are probably not eliminated by cytotoxic activi- 
ties of their target,  the CD8 + T  cells. 
Light Chain Usage.  Since the frequency of CD8.2-specific 
hybridomas was in the range of 1/200 to 1/860 and, in com- 
parison to other immunoglobulin heavy chain transgenic lines 
(12, 29, 31), and A. Iglesias, unpublished results), rather low, 
we expected that the transgenic/~ heavy chain would be able 
to combine only with a restricted subset of endogenous light 
chains to form CD8.2-specific antibodies. We therefore ex- 
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Anti-CD8.2 
Fusion  Spleen cells  Transgene  Myeloma partner  IgM  '+*  CD8.2  specific#  frequency 
A  Control  None  X63/F19 
AlS  C57BL/6  None  X63//z19  480  1  1/480 
A2s  C57BL/6  None  X63//z19  2,040  5  1/408 
A3s  ~16  None  X63//z19  1,300  13  1/100 
A  C57BL/6,B16  None  X63//z19  3,820  19  1/201 
B  CDS. 1 §  #19  "~  X63Ag8.0 
BI"  M4-316  #19 ~  X63Ag8,0  66  1  1/66 
B2S  M4-~16  /z19 '~  X63Ag8.0  500  4  1/125 
B3s  M4-~16  /x195~  X63Ag8.0  1,250  4  1/313 
B  p.19n-B16  ~19 '~  X63Ag8.0  1,816  9  1/201 
C  CD8.2 +  /~19  'm  X63Ag8.0 
ClS  M4-C57BL/6  /~19  '~n  X63Ag8.0  1,100  0 
C2  s  M4-C57BL/6  /x19  sm  X63Ag8.0  840  0 
C3s  M12-C57BL/6  /x19  s~  X63Ag8.0  540  0 
C4s  M12-C57BL/6  /z19  sm  X63Ag8.0  170  0 
C5s  M12-C57BL/6  /~19  sm  X63Ag8.0  1,000  0 
C6s  M8Y-C57BL/6  /~19  sm  X63Ag8.0  2,160  0 
C7S  M8Y-C57BL/6  /x19  ~m  X63AgS.0  360  0 
C8  s  MSY-C57BL/6  /~19  'm  X63AgS.0  440  0 
C9 II  M4-C57BL/6  /z19 'm  X63AgS.0  148  0 
C  ~19~-C57BL/6  ~19 n  X63Ag8.0  6,758  0  <1/6,758 
D  CD8.2 §  p,19'  X63Ag8.0 
DIS  M42-C57BL/6  /z19  ~  X63Ag8.0  980  2  1/440 
D2S  M85-C57BL/6  tz19  ~  X63Ag8.0  2,450  2  1/1,225 
D  #19'-C57BL/6  p,19'  X63Ag8.0  3,430  4  1/858 
* Calculated by counting  the IgMa  + wells on dilution plates. 
Obtained by FACS  |  analysis using supernatants from IgM  ~+ wells. 
s Spleen cells were stimulated for 3 d in vitro with 10/*g/ml LPS. 
II Spleen cells were stimulated in vivo by injecting 5 leg of LPS into  the spleen. 
amined  the  heterogeneity of these light  chains  by  one- 
dimensional IEF in polyacrylamide gels. A representative re- 
sult of this analysis is presented in Fig. 6. The t~ light chains 
of the six different, CD8.2-specific, hybridomas derived from 
three independent fusions (fusions A, B, and D; compare with 
Table 2) show an identical migration pattern (Fig. 6 A). This 
result, and the lack of any detectable microheterogeneity, sug- 
gest that these hybridomas  produce one x light chain that 
allows, in combination with the transgenic heavy chain, resto- 
ration of anti-CD8.2 speci{idty. Interestingly, the same specific 
light chain is also used in CD8.2-specific hybridomas obtained 
from unselected B cells fused to the X63/#19 transfected my- 
eloma line. Therefore, only one type of ~ light chain, which 
has a different isoelectric point than the K chain of the original 
anti-CDS.2  hybridoma  19/178,  allows  restoration  of the 
original CD8.2 specificity. We also analyzed the ~ light chain 
usage in other hybridomas that did not restore the original 
anti-CD8.2 specificity. Comparing 31 IgMa/x + hybridomas 
derived from 4/z19 CD8.1 § transgenic  mice, we observed 
seven K light chains with an identical migration pattern in 
the IEF-PAGE (Fig. 6 B), four additional pairs with an iden- 
tical but different migration behavior, and 20 other light chains 
each having an individual isoelectric point (data not shown). 
A comparable analysis of K  light chains derived from control 
hybridomas where normal spleen cells were fused with the 
X63//z19  transfected myeloma did not reveal large groups 
with an identical IEF-PAGE migration pattern (Fig. 6 C). 
Based on these results, we conclude that in transgenic  hy- 
bridomas the/z chain is preferentially expressed with partic- 
ular subsets of g light chains. 
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Figure 4.  Polyclonal  B cell activation induces anti-CD8.2 antibodies that bind to surface CD8 molecules  in/~19  s mice. Mice were injected intrasplen- 
ically  with 5/~g of LPS. Spleen cells were isolated after 4 d and analyzed  by flow cytometry. Lymphocytes  were gated according to their forward/sideward 
scatter distribution. The percentage of the individual splenocyte  subsets are given in each region. (A) RS3.1 (anti-IgM', fluorescence  2; PE) and 53-6.7 
(anti-CD8, fluorescence  1; FITC) double-stained cells from a control littermate (CL), the/zI9~ line M4 (M4/BL6), the kt19' line M42 (M42/BL6), 
all in the CD8.2 + C57BL/6 background, and from M4 in the congenic CD8.1 § #16 background (M4/~16). In contrast to all other lines, the CD8 + 
cells from M42 show a shift in fluorescence  2 (IgM  =+) from R3 to R2 due to the binding of transgenic antibodies to CD8 § T cells. (B) The same 
spleen cells double stained with MB86 for IgMb (fluorescence  2; PE) and 53-6.7 for CD8. In the/~19  s line M42, the transgenic/~, chains form mixed 
IgM molecules together with endogenous/~b chains. Binding of CD8.2-specific antibodies to CD8 surface molecules leads to the shift of CD8 + T 
cells towards fluorescence 2. 
Discussion 
Tolerance Induction in 1~19  sm Mice.  Tolerance may be im- 
posed on B lymphocytes by several mechanisms (4, 5, 8,  12, 
13,  32).  Recent investigations demonstrated  that  tolerance 
induction can be mediated by clonal deletion as well as by 
clonal anergy (5-12).  The induction can take place during 
early stages of B cell development when pre-B cells mature 
into slg +  small B  cells (5, 6)  as well as in mature B  lym- 
phocytes (9). In these transgenic mouse models, most B lym- 
phocytes carry the autospecific s-Ig receptor molecule. 
By introducing only the #  heavy chain gene of an anti- 
body with anti-CDS.2 specificity into the germline of mice, 
we chose a slightly different approach that allows the selec- 
tion of endogenous light chains during B lymphocyte matu- 
ration (17). The original antibody is specific for a single epi- 
tope of a membrane-bound protein antigen and recognizes 
specifically the CD8.2  allele encoded by the CD8 ot chain 
(16). To analyze the B cell tolerance status of our transgenic 
mice, we made use of the allelic differences between CD8.1 
and CD8.2.  We expected to find anti-CDS.2  antibodies at 
low frequencies resulting from the combination of the trans- 
genic heavy chain with appropriate endogenous light chains. 
As a control, we generated hybridomas from fusions between 
normal  spleen  cells  and  a  #19  'm  heavy chain  transfectant 
(X63/#19) of the myeloma line X63Ag8.0.  1 in 200 K light 
chains was found to restore the original anti-CD8.2 specificity 
(Table 2).  A  similar result was  obtained with  hybridomas 
generated from/~19 sm mice in a CD8.1 §  /316 background. 
In the absence of the antigenic CD8.2 o~ chain,  1 in 200 hy- 
bridomas produced anti-CDS.2  antibodies using the trans- 
genic/~ chain. This finding was also reflected by the presence 
of transgenic CD8.2-specific serum antibodies.  In mice ex- 
pressing  the antigenic CD8.2  oL chain,  we found no anti- 
CD8.2 serum antibodies nor were we able to detect CDS.2- 
specific hybridomas among the 6,700 clones analyzed from 
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Figure 5.  Binding to CD8.2 does not induce cytolysis  of anti-CD8.2- 
specific B lymphoma cells. The H2  d+ B lymphoma line K46 was trans- 
fected with the anti-CD8.2/~ and K  chains (K46pp [A and &]) and com- 
pared to the parental K46 line (O and O) in a cell-mediated lympholysis 
assay as described  in the Materials and Methods. The following  CTL were 
used: (21) CL96, H2Ka-restricted  anti-P815; (B) Tl12.3-2, H2Kb-restricted 
anti-TNP; (C) LD26.10.3-3, anti-H2D  d. K46pp and K46 target cells were 
labeled with StCr and incubated at different ratios with the CTL effector 
cells without (dashed lines) or with the addition of the lectin PHA (solid 
lines).  Specific killing was only observed for LD26 recognizing H2D  a. 
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the  /z19  sm  transgenic  mice.  These  data  show  that  in  a 
CD8.2 +  background,  the  /z19  sm  mice  are  tolerant.  At 
present, we cannot condusively distinguish between clonal 
anergy and clonal deletion of the autoreactive B cells. Since 
our detection assay involves the generation  of hybridomas 
from transgenic spleen cells that were polyclonally activated 
by LPS stimulation before the fusion, LPS refractile cells would 
have escaped our detection. For anergic B cells, it previously 
has been shown that within the first 3 d of stimulation with 
LPS they may respond only poorly in terms of Ig secretion 
although secretion although they are capable of proliferation 
(11, 33). An elongation of the incubation period for another 
4 d resuhs in almost equivalent clonal response as compared 
to controls.  Using t~ heavy chain transgenic  mice with an 
anti-ssDNA specificity,  Erikson et al. (12) were able to dem- 
onstrate that  anergized  B cells  could be efficiently used to 
generate ssDNA-specific transgenic hybridoma lines after in 
vivo LPS treatment.  For/z19 sm transgenic mice, in vivo LPS 
treatment does resuh in neither a detectable synthesis of high 
affinity anti-CD8.2  serum antibodies nor in the generation 
of anti-CD8.2 hybridomas (Table 2; Fig. 4). Using Ig trans- 
genic mice as a model for B cell tolerance,  there seems to 
be a difference between monovalent and repetitive self-antigens 
as tolerogens. Monovalent self-antigens,  like soluble proteins, 
seem to induce clonal anergy (8-11, 28, 32, 33) or seem to 
have no tolerizing capacity (6, 34), whereas repetitive self- 
antigens,  which  also  can  be  presented  in  the  form  of 
membrane-bound molecules, appear to result in clonal dele- 
tion  of autoreactive B cells  (5,  6,  33,  34).  Since the CD8 
molecule is expressed as a membrane protein, our resuhs sug- 
gest a deleting mechanism acting on the anti-CD8.2 B cells 
in the presence of the antigenic CD8.2 o~ chain. This conclu- 
sion is also supported by other systems where anergized B 
cells were shown to be rescued in hybridomas (12). 
We also asked whether the immune system would be able 
to suppress the expression of transgenic autoantibodies when 
the transmembrane  exons of the/~ transgene were deleted. 
The resulting construct allows expression only of the secreted 
form of the transgenic/z chain. Thus, in the presence of the 
CD8.2 antigen,  the B cells should not be a target for toler- 
ance induction. Searching for anti-CD8.2 serum antibodies, 
we were unable to find them in the majority of the tested 
/*19  s mice. This observation is most probably due to the lack 
of alldic  exclusion  in  transgenic/is  lines  (17,  29),  which 
leads to coexpression of transgenic and endogenous # chains 
in B cells. As a consequence, in some mice the avidity of such 
hybrid anti-CD8.2 IgM  ab antibodies may have been lowered. 
They may have,  therefore,  remained undetected.  However, 
our analysis of their tolerance status at a single cell level proved 
them to be nontolerant:  hybridomas generated from spleen 
cells of M42 and M85 mice revealed in both cases anti-CD8.2- 
specific clones (1/858 hybridomas; Table 2). Their frequency 
is  about  fourfold  lower  if compared  to  the  /~19  ~  lines. 
Again,  this lower anti-CD8.2  antibody frequency may be 
ascribed to the problem of detecting hybrid anti-CD8.2 an- 
tibodies.  The  nontolerance  of/~19  s mice was further  sup- 
ported by in vivo stimulation  of their  splenocytes by LPS 
injection. This led to an increase of the secreted anti-CD8.2 Figure 6.  IEF-PAGE  analysis of the g light chain 
pattern in transgenic and control hybridomas. Super- 
natants from hybridomas of the fusions A, 13, and D 
(see Table 2) were separated on IEF-PAGE, blotted, 
and developed with peroxidase labeled and-mouse r 
antibodies as described  in Materials and Methods. (A) 
The comparison of the original 19/178 r chain with 
r  chains produced by CDS.2-specific IgM  a+ hybrid- 
omas A41, A49, A64, B2.9, B2.49, D53.11 derived 
from three independent fusions. All hybridomas ex- 
press r chains with identical isoelectric points, which 
are different from the r chain of 19/178. Hybridoma 
A49 is probably not monoclonal since it shows an ad- 
ditional r chain. The original 19/178 line synthesizes 
two light chains. Only one of tliem contributes to its 
anti-CDS.2 specificity  and is marked by arrows. It was 
cloned and cotransfected together with the specific  # 
chain into X63Ag8.0 (X63a-CD8).  (B) Preferential 
usage of r light chains in eight different hybridomas. 
Although the transgene-positive  hybridomas were de- 
rived from two independent fusions (B2 and B3; com- 
pare with Table 2) using transgenic spleen cells, they 
express  with the exception  of  B2.40 r chains with iden- 
tical isoelectric points. (C) No preference in the as- 
sociation of r chains with the and-CD8.2/z chain in 
hybridomas obtained after fusing 316 spleen  cells  with 
the transfectoma X63//~19. 
antibodies,  which were found to be bound to the CD8 sur- 
face molecules of all CD8 § T  cells (Fig. 4).  The binding did 
not  eliminate  the  CD8*  T  cells,  as it  was  observed when 
the original anti-CD8.2 IgG2A antibody 19/178 (35) recog- 
nizing the same epitope was injected into mice. Since many 
inbred mouse strains have very low levels of complement ac- 
tivity (36)  and because injected  IgM  anti-T cell  antibodies 
are much less efficient in depleting T  lymphocytes than many 
IgG antibodies (37), the in vivo synthesized transgenic anti- 
CD8.2  IgM  * antibodies  may simply bind  to  the  CD8  sur- 
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population. For the/~19  'm line M4, we did not observe the 
synthesis of high affinity anti-CD8.2  antibodies after LPS 
injection. We cannot, however, rule out an increase in trans- 
genic low affinity anti-CD8 antibodies. Those may be either 
present at low concentrations or they may have been com- 
peted out by the labeled high affinity anti-CD8 antibodies 
during FACS  |  analysis.  In the case of the/~19" mice, their 
presence may have been obscured by the expression of high 
affinity anti-CD8.2  antibodies. 
Role ofCytotoxic T  Cells.  Tolerance induction of B cells 
has been demonstrated to occur both at early stages of B lym- 
phocyte development during the transition from pre-B to B 
cells (6) as well as for mature B cells (9). One might envisage 
that B cells autoreactive for self-determinants expressed on 
cytotoxic T  cells are controlled by CTL effector functions. 
Here, we could demonstrate that tolerance is efficiently im- 
posed on B cells even if their T cell compartment is largely 
deficient. We also could show that the surface expression of 
the anti-CD8.2  Ig receptor on the B lymphoma line K46 
does not mediate specific killing in vitro. Both results argue 
against a  CTL-dependent control of the autospecific anti- 
CD8.2  B ceils. 
Light Chain Selection.  Comparing hybridomas from nor- 
mal and from transgenic spleen cells, we found with similar 
frequencies only one light chain that was able to comple- 
ment for the original anti-CDS.2 specificity (Fig. 6 A). This 
contrasts observations made with other Ig # heavy chain trans- 
genic mice. There, the usage of the original light chain (gt67 
for anti-phosphoryl-choline specificity [38]) was found to be 
increased. This expansion of B cells with selected light chains 
was interpreted to be due to idiotypic interactions and/or to 
exposure to antigens during B lymphocyte maturation. In 
analogy, we found that 20% of the transgenic hybridomas 
used K  light chains with identical isoelectric points that were 
different from the anti-CDS.2-specific light chains. This con- 
trasts with our results obtained for hybridomas derived from 
normal spleen cells fused to the transfectoma X63//~19. There 
we found a large variety of K light chains with unique iso- 
electric points that were associated with the #  heavy chain. 
This shows, that the anti-CD8.2 # chain is able to combine 
with many different light chains. A similar result was found 
in other hybridomas for artificial heavy/light chain combi- 
nations (39). Interactions of heavy and light chains are known 
to  vary widely in  their  pairing  affinity,  and  preferential 
heavy/light chain associations are well documented in com- 
petition experiments (40).  In analogy, many combinations 
of endogenous light chains with the transgenic #  chain in 
vivo could also have low pairing affinities.  This could pre- 
vent their selection into the pool of peripheral B cells.  In 
addition, other mechanisms could lead to the preferential ex- 
pression of light chain subsets together with a given heavy 
chain. Similar to T cells, B cells could be negatively or posi- 
tively selected or the selective expansion of particular B cell 
subsets could be driven by antigenic challenge, the size of 
the available light chain repertoire, and/or on idiotypic in- 
teractions. These processes,  which should occur after light 
chain rearrangement in pre-B cells, are now subject of fur- 
ther investigations. 
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